Lexeo Therapeutics, Inc.
LXEO
$4.61
-$0.12-2.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 44.03% | 39.45% | 13.55% | 6.13% | -5.45% |
| Gross Profit | -44.03% | -39.45% | -13.55% | -7.17% | 4.47% |
| SG&A Expenses | 103.00% | 105.92% | 136.75% | 101.88% | 62.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.36% | 54.38% | 35.82% | 23.49% | 6.88% |
| Operating Income | -60.36% | -54.38% | -35.82% | -24.48% | -7.78% |
| Income Before Tax | -57.46% | -48.11% | -29.67% | -21.16% | -6.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.46% | -48.11% | -29.67% | -21.16% | -6.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.46% | -48.11% | -29.67% | -21.16% | -6.09% |
| EBIT | -60.36% | -54.38% | -35.82% | -24.48% | -7.78% |
| EBITDA | -60.85% | -54.76% | -36.03% | -24.41% | -7.45% |
| EPS Basic | 85.18% | 90.65% | 92.28% | 62.58% | 44.33% |
| Normalized Basic EPS | 85.18% | 90.65% | 92.28% | 62.58% | 44.33% |
| EPS Diluted | 85.18% | 90.65% | 92.28% | 62.58% | 44.33% |
| Normalized Diluted EPS | 85.18% | 90.65% | 92.28% | 62.58% | 44.33% |
| Average Basic Shares Outstanding | 177.47% | 496.95% | 1,599.32% | 1,112.74% | 628.82% |
| Average Diluted Shares Outstanding | 177.47% | 496.95% | 1,599.32% | 1,112.74% | 628.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |